Inmune Bio, Inc.
INMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001711754
No open-market purchases or sales by Inmune Bio, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $7.08M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 82
- 13F valueReported value at the end of Q2 2026
- $7.08M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding INMB, Q2 2026
No superinvestor reported holding INMB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Inmune Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 (view filing) | Sep 30 | Same day | Moss David JChief Financial Officer | PPurchase | +10.0K | $5.29 | +$52.9K | +0.8%1.29M after | |
| Sep 16, 2024 (view filing)8:48 PM ET | Sep 12 | 4 days | Tesi Raymond JosephPresident and CEO | PPurchase | +15.4K | $6.38 | +$98.0K | +1.0%1.55M after | |
| Sep 16, 2024 (view filing)8:48 PM ET | Sep 12 | 4 days | Tesi Raymond JosephPresident and CEO | PPurchase | +15.4K | $0.125 | +$1.92K | –15.4K after | Derivative |
| Sep 16, 2024 (view filing)8:47 PM ET | Sep 12 | 4 days | Moss David JChief Financial Officer | PPurchase | +7.69K | $6.38 | +$49.0K | +0.6%1.28M after | |
| Sep 16, 2024 (view filing)8:47 PM ET | Sep 12 | 4 days | Moss David JChief Financial Officer | PPurchase | +7.69K | $0.125 | +$961.25 | –7.69K after | Derivative |
| Jun 26, 2024 (view filing) | Jun 25 | 1 day | Juda ScottDirector | PPurchase | +5.00K | $7.27 | +$36.4K | +7.5%71.6K after | |
| Apr 24, 2024 (view filing)2:10 PM ET | Apr 19 | 5 days | Moss David JCFO, Treasurer & Secretary | PPurchase | +18.0K | $8.32 | +$150.0K | +1.4%1.27M after | Amended |
| Apr 24, 2024 (view filing)2:10 PM ET | Apr 19 | 5 days | Moss David JCFO, Treasurer & Secretary | PPurchase | +18.0K | $0.125 | +$2.25K | –18.0K after | AmendedDerivative |
| Apr 24, 2024 (view filing)2:08 PM ET | Apr 19 | 5 days | Tesi Raymond JosephPresident and CEO | PPurchase | +18.0K | $8.32 | +$150.0K | +1.2%1.54M after | Amended |
| Apr 24, 2024 (view filing)2:08 PM ET | Apr 19 | 5 days | Tesi Raymond JosephPresident and CEO | PPurchase | +18.0K | $0.125 | +$2.25K | –18.0K after | AmendedDerivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Inmune Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 706,424 | $1.15M | 0.00% | +19,409+2.8% | Added |
| AQR Capital Management LLC | 662,218 | $1.08M | 0.00% | +391,901+145.0% | Added |
| BlackRock, Inc. | 311,613 | $507.9K | 0.00% | −882,499−73.9% | Reduced |
| Raymond James Financial Inc | 212,995 | $347.2K | 0.00% | +9,750+4.8% | Added |
| Geode Capital Management, LLC | 190,215 | $310.3K | 0.00% | −304,754−61.6% | Reduced |
| Goldman Sachs Group Inc | 185,245 | $301.9K | 0.00% | −46,341−20.0% | Reduced |
| Millennium Management LLC | 159,559 | $260.1K | 0.00% | +159,559 | New |
| Susquehanna International Group, LLP | 158,452 | $258.3K | 0.00% | −35,939−18.5% | Reduced |
| Jane Street Group, LLC | 134,232 | $218.8K | 0.00% | +83,288+163.5% | Added |
| UBS Group AG | 110,413 | $180.0K | 0.00% | −142,927−56.4% | Reduced |